Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical Co's Accounts Payable for the quarter that ended in Jun. 2026 was MXN17,441 Mil.
Chugai Pharmaceutical Co's quarterly Accounts Payable
declined
from Dec. 2025 (MXN14,695 Mil) to Mar. 2026 (MXN12,219 Mil) but then
increased
from Mar. 2026 (MXN12,219 Mil) to Jun. 2026 (MXN17,441 Mil).
Chugai Pharmaceutical Co's annual Accounts Payable
declined
from Dec. 2023 (MXN13,259 Mil) to Dec. 2024 (MXN8,861 Mil) but then
increased
from Dec. 2024 (MXN8,861 Mil) to Dec. 2025 (MXN14,695 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co Accounts Payable Calculation
Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.
What does a Accounts Payable of MXN17,441 Mil mean?
Chugai Pharmaceutical Co (MEX:4519N) has a Accounts Payable of MXN17,441 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Chugai Pharmaceutical Co and its competitors.
Is Chugai Pharmaceutical Co's Accounts Payable too high?
Chugai Pharmaceutical Co's current Accounts Payable is MXN17,441 Mil. Overall, Chugai Pharmaceutical Co has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Accounts Payable compare to LLY and JNJ?
Chugai Pharmaceutical Co's Accounts Payable of MXN17,441 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Chugai Pharmaceutical Co and its competitors. Chugai Pharmaceutical Co's current Accounts Payable is MXN17,441 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Chugai Pharmaceutical Co (MEX:4519N) has a current Accounts Payable of MXN17,441 Mil. The stock's GF Value™ is MXN967.27, compared to a current price of MXN825.61 — trading 14.6% below its estimated fair value. The current Accounts Payable is MXN17,441 Mil. Chugai Pharmaceutical Co's overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Chugai Pharmaceutical Co (MEX:4519N), the current Accounts Payable is MXN17,441 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (MEX:4519N) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of MXN825.61 is trading 14.6% below its estimated GF Value™ of MXN967.27.
Key valuation signals for MEX:4519N:
Accounts Payable: MXN17,441 Mil
GF Value™: MXN967.27 vs. price of MXN825.61 (14.6% below fair value)
No single metric tells the full story. See the MEX:4519N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
95GF Score
Get the complete analysis for MEX:4519N
Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:4519N has been successfully added to your 
